注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Altimmune Inc是一家临床阶段的生物制药公司,专注于开发肥胖症和肝病的治疗方法。该公司的主要候选产品pemvidutide(INN,原名ALT-801)是一种GLP-1/胰高血糖素双受体激动剂,正在开发用于治疗肥胖和非酒精性脂肪性肝炎(NASH)。该公司还正在开发HepTcell,这是一种免疫治疗剂,旨在实现慢性乙型肝炎的功能性治疗。该公司已经启动了HepTcell的II期临床试验,并在II期和I期临床开发中使用培维多肽治疗多种适应症。它正在美国、英国、加拿大、德国和西班牙进行HepTcell的II期临床试验,并在澳大利亚进行培维多肽I期临床试验。其全资子公司包括Altimmune,LLC、Altimmune UK,Limited、Spitfire Pharma,LLC和Altimmune AU Pty,Limited。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Wayne F. Pisano | 66 | 2018 | Independent Director |
David J. Drutz | 82 | 2011 | Independent Director |
Mitchel B. Sayare | 73 | 2010 | Independent Chairman |
Philip L. Hodges | 52 | 2017 | Independent Director |
Vipin K. Garg | 63 | 2018 | President, CEO & Director |
Klaus O. Schafer | 74 | 2017 | Independent Director |
Diane Kathryn Jorkasky | 72 | 2020 | Independent Director |
John M. Gill | 72 | 2004 | Independent Director |
Caroline M. Apovian | - | 2022 | Member of Obesity Scientific Advisory Board |
Louis J. Aronne | 68 | 2022 | Member of Obesity Scientific Advisory Board |
Robert F. Kushner | - | 2022 | Member of Obesity Scientific Advisory Board |
Donna Ryan | - | 2022 | Member of Obesity Scientific Advisory Board |
Juan Pablo Frias | - | 2022 | Member of Obesity Scientific Advisory Board |
Daniel Joshua Drucker | - | 2022 | Member of Obesity Scientific Advisory Board |
Samuel Klein | - | 2022 | Member of Obesity Scientific Advisory Board |
Catherine Angell Sohn | 71 | 2023 | Independent Director |
Lee M. Kaplan | - | 2023 | Member of Obesity Scientific Advisory Board |
Rohit Loomba | - | 2022 | Member of Mash Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核